GlassScriptPhysician profile
Joseph L Brown
NPI 1245908292
$3,523.32
in general payments reported to CMS, 2019-2025
24 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.03 · 2022: $33.53 · 2023: $790 · 2024: $1,640 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,466.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $839.47 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $514.95 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $420.51 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $373.65 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $211.80 | 2023-2025 | |
| Glaxosmithkline, LLC. | $151.70 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $136.07 | 2022-2024 | Rexulti |
| Amgen INC. | $133.74 | 2023-2025 | Prolia, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.07 | 2021-2025 | Jardiance, Spiriva Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.37 | 2023-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $80.87 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $67.32 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $55.44 | 2024 | Veozah |
| Esperion Therapeutics, INC. | $55.10 | 2024 | Nexletol |
| Grifols USA, LLC | $51.43 | 2024 | Prolastin-C Liquid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $41.40 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.78 | 2025 | Caplyta |
| Dexcom, INC. | $40.38 | 2024 | Dexcom G6 Transmitter |
| Nevro Corp. | $22.87 | 2023 | Senza |
| Teva Pharmaceuticals USA, INC. | $19.43 | 2023 | Austedo |
| Antares Pharma, INC. | $18.96 | 2025 | Xyosted |
| Sanofi Pasteur INC. | $18.24 | 2023 | |
| Silk Road Medical, INC. | $18.23 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Idorsia Pharmaceuticals US INC | $13.54 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.